Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …

Hematopoietic stem cells (HSCs) are crucial for the life maintenance of bio-organisms.
However, the mechanism of HSC regulation is intricate. Studies have shown that there are …

Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been
shown to improve outcomes in elderly patients with acute myeloid leukemia (AML) …

Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD)
or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de …

Abstract Cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) gene is one of the
sub-members of CYP450 family member and it encodes with the families of drug …

B/T mixed phenotype acute leukemia (MPAL) is a rare aggressive leukemia. Three cases of
B/T MPAL were identified with comprehensive immunophenotypic, cytogenetic, and …

This study aimed to investigate the clinical characteristics and prognosis of Runt‐related
transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing …

Background: Acute myeloid leukemia (AML) is a biologically heterogenous disease arising
in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads …

Venetoclax is a BH3-mimetics agent interacting with the anti-apoptotic protein BCL2,
facilitating cytochrome c release from mitochondria, subsequent caspases activation, and …